TapImmune Inc (TPIV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

TapImmune Inc (TPIV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH81869D
  • |
  • Pages: 57
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

TapImmune Inc (TapImmune) is a clinical-stage immuno-oncology company focus on the development of innovative peptide, gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company's pipeline products include TPIV 200, which is intended for the treatment of ovarian and triple-negative breast cancers; and TPIV 100/110, which is intended for the treatment of breast cancers. TapImmune's technologies include peptide antigen technologies and DNA expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells. The company develops next-generation T-cell vaccines for treating women's cancers. It collaborates with industry and clinical leaders for clinical development of breast cancer vaccine technology. TapImmune is headquartered in Jacksonville, Florida, the US.

TapImmune Inc (TPIV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TapImmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

TapImmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

TapImmune Inc, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

TapImmune Prices Private Placement of Shares for USD70 Million 11

Partnerships 13

Vaccine & Gene Therapy Institute Enters into Research Agreement with TapImmune 13

Merger 14

TapImmune to Merge with Marker Therapeutics 14

Licensing Agreements 16

TapImmune Exercises Option for Licensing Agreement with Mayo Clinic 16

TapImmune Exercises Option for Licensing Agreement with Mayo Clinic for HER2/neu Vaccine Technology 17

Equity Offering 18

TapImmune Raises USD3.1 Million in Private Placement 18

TapImmune Files Registration Statement to Raise Funds through Public Offering of Shares 19

TapImmune Raises USD2 Million in Private Placement of Shares 20

TapImmune Raises USD6.2 Million in Private Placement of Shares 22

TapImmune Raises USD0.67 Million in Private Placement of Shares upon Exercise of Warrants 23

TapImmune Raises USD6 Million in Private Placement of Shares upon Exercise of Warrants 24

TapImmune to Raise USD2.5 Million in Private Placement of Units 25

TapImmune Raises USD2.5 Million in Private Placement of Shares upon Exercise of Warrants 26

TapImmune to Raise USD5 Million in Private Placement of Shares upon Exercise of Warrants 27

TapImmune Receives USD1 Million of Investment from Eastern Capital 28

TapImmune to Raise USD1.5 Million in Private Placement of Units 29

TapImmune Inc-Key Competitors 31

TapImmune Inc-Key Employees 32

TapImmune Inc-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

Apr 05, 2018: TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update 34

May 31, 2017: TapImmune Provides First Quarter 2017 Corporate and Clinical Update 35

Mar 14, 2017: TapImmune Provides Year End 2016 Corporate and Clinical Update 37

Corporate Communications 39

May 22, 2018: TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center 39

Dec 06, 2017: TapImmune Appoints Richard Kenney, M.D., F.A.C.P., as Acting Chief Medical Officer 41

Sep 25, 2017: TapImmune Appoints Peter Hoang as President and Chief Executive Officer 42

Apr 28, 2017: TapImmune Announces Change in Management and Board of Directors 43

Clinical Trials 44

Nov 14, 2017: TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer 44

Aug 08, 2017: TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments 45

Jun 27, 2017: TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer 46

Mar 14, 2017: TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer 47

Feb 15, 2017: TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review 48

Feb 02, 2017: TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials 49

Jan 24, 2017: TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial 50

Jan 10, 2017: TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients 51

Other Significant Developments 52

Nov 15, 2017: TapImmune Provides Third Quarter 2017 Corporate and Clinical Update 52

Oct 18, 2017: A Personal Letter to the Shareholders from TapImmune's New Chief Executive Officer 54

Aug 31, 2017: TapImmune Provides Second Quarter 2017 Corporate and Clinical Update 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57

List of Figures

TapImmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TapImmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

TapImmune Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TapImmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

TapImmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TapImmune Inc, Deals By Therapy Area, 2012 to YTD 2018 9

TapImmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

TapImmune Prices Private Placement of Shares for USD70 Million 11

Vaccine & Gene Therapy Institute Enters into Research Agreement with TapImmune 13

TapImmune to Merge with Marker Therapeutics 14

TapImmune Exercises Option for Licensing Agreement with Mayo Clinic 16

TapImmune Exercises Option for Licensing Agreement with Mayo Clinic for HER2/neu Vaccine Technology 17

TapImmune Raises USD3.1 Million in Private Placement 18

TapImmune Files Registration Statement to Raise Funds through Public Offering of Shares 19

TapImmune Raises USD2 Million in Private Placement of Shares 20

TapImmune Raises USD6.2 Million in Private Placement of Shares 22

TapImmune Raises USD0.67 Million in Private Placement of Shares upon Exercise of Warrants 23

TapImmune Raises USD6 Million in Private Placement of Shares upon Exercise of Warrants 24

TapImmune to Raise USD2.5 Million in Private Placement of Units 25

TapImmune Raises USD2.5 Million in Private Placement of Shares upon Exercise of Warrants 26

TapImmune to Raise USD5 Million in Private Placement of Shares upon Exercise of Warrants 27

TapImmune Receives USD1 Million of Investment from Eastern Capital 28

TapImmune to Raise USD1.5 Million in Private Placement of Units 29

TapImmune Inc, Key Competitors 31

TapImmune Inc, Key Employees 32

TapImmune Inc, Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

TapImmune Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17848
Site License
USD 500 INR 35695
Corporate User License
USD 750 INR 53543

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com